Marshall Wace, LLP Chinook Therapeutics, Inc. Transaction History

Marshall Wace, LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$18.66 - $38.58 $199,662 - $412,806	10,700 New	10,700 $411,000
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $2.54 Million - $3.79 Million	201,617 Added 316.34%	265,351 $4.64 Million
Q1 2022 May 16, 2022	SELL	$12.02 - $16.69 $1.48 Million - $2.06 Million	-123,293 Reduced 65.92%	63,734 $1.04 Million
Q4 2021 Feb 14, 2022	BUY	$10.69 - $16.83 $2 Million - $3.15 Million	187,027 New	187,027 $3.05 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.